Navigation Links
Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
Date:5/22/2012

CAMBRIDGE, Mass. (May 22, 2012) Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

Researchers have theorized that inhibiting HSP90 just might render breast cancer cells less likely to escape the challenge posed by cutting off their ability to use estrogen. Such is the rationale for a new clinical trial that has begun enrolling patients this week.

In the trial, patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer will be treated either with fulvestrant, a drug currently marketed by AstraZeneca as Faslodex, or with a combination of fulvestrant and ganetespib, a drug which inhibits HSP90 and is now in clinical development by Synta Pharmaceuticals.

The trial's principal investigator is Nancy Lin, the Clinical Director of the Breast Oncology Center at Dana-Farber Cancer Institute and Assistant Professor at Harvard Medical School. Lin is collaborating with Luke Whitesell, an oncologist and senior research scientist in the lab of Whitehead Institute Member Susan Lindquist.

Breast cancer is the most common cause of cancer-related deaths in women worldwide. An estimated 40,000 women in the United States are expected to die from the disease this year. In the developed world, approximately two-thirds of all breast cancer cases are ER+. Highly dependent on their estrogen receptors for growth and survival, these tumor cells are sensitive to hormonal therapies, making drugs like tamoxifen and fulvestrant effective first-line therapies for many patients.

However, in patients with breast cancers that recur or metastasize after initial hormonal therapy, long-term remission is uncommon and life expectancy is about three years. Currently, these patients have few therapeutic options. By adding an HSP90 inhibitor, Lin and Whitesell hope to hobble the resistant cancer cells, making them less likely to escape the effects of fulvestrant.

Lin likens a malignant tumor to a car on a highway in a high-speed chase. As the car hurtles down the road, police may erect a roadblock to stop it. In the case of ER+ breast cancer, that roadblock is hormonal therapy. Unfortunately, a tumor may mutate enough to find a detour around the roadblock and continue on its destructive course. Adding a heat shock protein inhibitor to the mix may thwart the cancer's ability to find an alternate route.

"Because of the way HSP90 inhibitors work, it's like throwing a bunch of roadblocks across a bunch of detours," says Lin, who will be running the clinical part of the trial. "So the idea is to try to block these alternative pathways that might allow the tumor to grow."

"Inhibiting HSP90 in tumors may not cause them to roll over and die," says Whitesell, who with support from Susan G. Komen for the Cure will be analyzing blood and tissue samples from trial participants. "But it may change the biology of the cancer to make it more susceptible to other things that we already know work against the cancer, like fulvestrant."

The trial's premise is based on years of work the Lindquist lab has conducted on heat shock proteins. That experience is invaluable, according to Sandro Santagata, a pathologist in the Lindquist lab who will also be examining patient tissue samples.

"The Lindquist lab has a great basic scientific understanding of the biology of the heat shock system," says Santagata. "That foundation will hopefully provide important insights to increase the likelihood of success for this trial and if it doesn't work, an understanding of why. That's always a tricky part. Figuring out the 'why' is always complicated so it helps to have people like Susan and Luke who have a lot of background in the system you're studying."

For her part, Lindquist says she is looking forward to testing the therapeutic potential of targeting HSP90.

"I am very excited about the translational applications of some of the basic science we have been working on over the years," says Lindquist, who is also a professor of biology at MIT and a Howard Hughes Medical Institute (HHMI) Investigator. "Luke and I are thrilled to be working with Nancy Lin."


'/>"/>

Contact: Nicole Giese Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... In any ... Regardless of the talent of your dental team at presenting treatment, there will always ... invest a lot of time and money on best practices when it comes to ...
(Date:5/26/2017)... ... , ... Mediaplanet is proud to announce the launch of its newest edition ... readers on how to take care of all aspects of their skin. , On ... Dancing with the Stars professional, Witney Carson, shares her journey with the disease that ...
(Date:5/26/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) ... legislative activity and the latest regulatory concerns impacting RBMA members. The Legislative Education ... will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner in Mclean, ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the ... narrowly passed the U.S. House on May 4, would result in 23 million Americans ... continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/4/2017)... -- Fortuna Fix Inc. (" Fortuna "), a private, clinical-stage ... the need for embryonic and fetal stem cells by using ... Fortuna announced today the launch of its ... MD, PhD; Father Kevin FitzGerald , S.J., PhD; Col. ... James Giordano , PhD. "We are excited and ...
Breaking Medicine Technology: